IV Fosphenytoin for Acute Trigeminal Neuralgia: What the Phase 3 Trial Means for Rescue Care

Rapid relief addresses a difficult treatment gap

Severe trigeminal neuralgia can leave patients unable to speak, eat, drink or take their usual oral medication without provoking repeated electric-shock-like pain. The multicenter randomized phase 3 trial indexed by PubMed reports that intravenous fosphenytoin provided greater immediate pain relief than placebo during an acute exacerbation. That finding matters because standard first-line medicines, particularly carbamazepine and oxcarbazepine, are primarily used for ongoing control rather than rapid rescue.

The evidence supports a narrow conclusion: intravenous fosphenytoin can suppress pain quickly in selected patients with severe trigeminal neuralgia when oral management is inadequate or impractical. It does not show that the drug should become routine outpatient therapy, nor does it establish superiority over every other rescue strategy.

Fosphenytoin is a water-soluble prodrug that is converted to phenytoin after administration. Its presumed relevance to trigeminal neuralgia is sodium-channel blockade, which may reduce the abnormal, high-frequency neuronal firing associated with paroxysmal attacks. A rapid intravenous effect is clinically plausible, but biological plausibility alone would not be enough; the randomized comparison is what strengthens the efficacy claim.

What the phase 3 trial adds

The peer-reviewed study was a multicenter, phase 3 randomized trial comparing intravenous fosphenytoin with placebo in patients presenting with an acute, severe exacerbation of trigeminal neuralgia. The principal question was immediate analgesia after infusion, rather than long-term attack prevention. Participants were followed over an acute observation period, so the study addresses early pain control rather than outcomes over subsequent months.

The trial reported a clinically meaningful early advantage for fosphenytoin, supporting a causal interpretation within the enrolled population because treatment was randomly assigned and placebo controlled. The supplied PubMed record, however, does not provide enough independently verifiable information here to reproduce the complete arm-level sample size, effect estimate, confidence interval and adverse-event table without risking transcription error. Those numerical details should be taken directly from the peer-reviewed article before protocol adoption.

That distinction is important. “Phase 3” indicates a later-stage confirmatory study, but it does not automatically mean that the intervention has US regulatory approval for the condition, that the evidence is broad enough for every emergency department, or that longer-term benefit has been established.

The trial also examined rescue in a specific syndrome. Trigeminal neuralgia is characterized by recurrent, brief, usually unilateral facial pain in the distribution of the trigeminal nerve, often triggered by innocuous stimuli. Continuous facial pain, sensory loss, fever, rash, dental disease, visual symptoms or a new neurologic deficit should prompt consideration of other diagnoses or secondary causes rather than automatic use of a trigeminal neuralgia rescue pathway.

Implications for emergency and inpatient care

The study supports considering intravenous fosphenytoin where severe, clinically established trigeminal neuralgia requires immediate control and usual oral treatment is failing, not tolerated or temporarily impossible. In practical terms, that points toward emergency departments, observation units or inpatient settings with appropriate cardiovascular monitoring and staff familiar with parenteral antiseizure drugs.

This is not simply an intravenous version of a routine home analgesic. Fosphenytoin can cause hypotension and cardiac arrhythmias, particularly when administered too rapidly. The US prescribing information calls for controlled infusion and cardiovascular monitoring. Neurologic adverse effects associated with phenytoin exposure, including dizziness, nystagmus, ataxia and somnolence, can also complicate assessment and discharge.

Those requirements shape the care pathway. A treatment that relieves pain within hours could prevent dehydration, restore oral intake and reduce exposure to opioids that often perform poorly against brief, trigger-evoked neuralgic attacks. Conversely, monitoring needs and infusion-related risks make the drug poorly suited to unmonitored clinics or home administration.

In the United States, fosphenytoin is approved for seizure-related indications and short-term substitution for oral phenytoin, not specifically for trigeminal neuralgia. Use for acute trigeminal neuralgia is therefore off-label. The phase 3 findings can inform institutional review and clinical pathways, but they do not themselves change the FDA-approved indication.

Acute relief should also open a bridge to the next decision. Clinicians still need to review maintenance therapy, adherence, drug interactions, sodium and liver-related risks where relevant, and whether the patient needs neurology or neurosurgical assessment. Established guidance continues to place carbamazepine or oxcarbazepine at the center of ongoing drug treatment, while surgery may be considered when medicines are ineffective or poorly tolerated.

Important limits on the evidence

The study concerns short-term rescue, not durable disease modification. It cannot establish whether fosphenytoin reduces recurrence, prevents another emergency visit or improves quality of life beyond the acute observation window. It also does not show that repeated rescue infusions are safe or effective.

Generalizability deserves scrutiny. Patients enrolled in a controlled trial may have clearer diagnoses, fewer contraindications and more consistent monitoring than patients seen in routine emergency care. Older adults, people with conduction disease or hypotension, pregnant patients, and those taking interacting medicines may require considerations that a modest acute trial cannot fully resolve.

The comparator also matters. Placebo control establishes whether fosphenytoin has an acute pharmacologic effect, but it does not determine how the drug compares with intravenous lidocaine, other specialist rescue approaches or accelerated optimization of oral therapy. Head-to-head trials and pragmatic studies would better answer those care-delivery questions.

Finally, safety interpretation requires the complete publication, including treatment-emergent adverse events, infusion interruptions, serious events, funding and author conflicts. A positive efficacy endpoint should not be separated from those details when hospitals consider adding fosphenytoin to an acute facial-pain protocol.

Questions clinicians ask

Does this evidence justify routine emergency-department use?

It supports monitored consideration for carefully selected patients with severe, established trigeminal neuralgia who need rapid rescue. It does not support automatic use for undifferentiated facial pain, routine outpatient infusion or treatment without attention to contraindications, infusion precautions and alternative diagnoses.

Is intravenous fosphenytoin FDA-approved for trigeminal neuralgia?

No. In the United States, fosphenytoin is approved for specified seizure-related uses and short-term parenteral substitution for oral phenytoin. Using it to relieve an acute trigeminal neuralgia exacerbation remains off-label, even when supported by randomized trial evidence.

Does acute relief replace carbamazepine or oxcarbazepine?

No. The trial evaluated immediate rescue during severe pain, whereas carbamazepine and oxcarbazepine remain established options for ongoing attack prevention. Once pain is controlled, the maintenance regimen and the need for specialist or surgical evaluation still require review.

What evidence is still needed?

Useful next steps include head-to-head comparisons with other rescue strategies, larger safety datasets and studies measuring recurrence, oral intake, discharge, repeat emergency visits and patient-reported function. Research should also clarify which clinical subgroups gain enough benefit to outweigh cardiovascular and neurologic risks.

References

1. IV Fosphenytoin for Acute Trigeminal Neuralgia — PubMed, 2026 2. Trigeminal neuralgia: a practical guide — BMJ, 2021 3. Cerebyx: Drugs@FDA Application Overview — US Food and Drug Administration, 2025 4. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia — Neurology, 2008